219 related articles for article (PubMed ID: 11419827)
21. Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
Becker TL; Maróstica M; Ribeiro ML; de Mendonça S; Gambero A; Pedrazzoli J
Int Immunopharmacol; 2004 Aug; 4(8):1051-7. PubMed ID: 15222979
[TBL] [Abstract][Full Text] [Related]
22. [2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
Leonhardt U; Ritzel U; Ramadori G
Internist (Berl); 1996 Sep; 37(9):944-9; discussion 949. PubMed ID: 8964694
[No Abstract] [Full Text] [Related]
23. Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
de Boer SY; v d Meeberg PC; Siem H; de Boer WA
Neth J Med; 2003 Jun; 61(6):218-22. PubMed ID: 12956102
[TBL] [Abstract][Full Text] [Related]
24. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
25. Proton-pump inhibitors: three of a kind?
Bateman DN
Lancet; 1997 Jun; 349(9066):1637-8. PubMed ID: 9186377
[No Abstract] [Full Text] [Related]
26. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
van Zyl J; van Rensburg C; Vieweg W; Fischer R
Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
[TBL] [Abstract][Full Text] [Related]
27. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial.
Svoboda P; Kantorová I; Ochmann J; Doubek J; Kozumplík L; Marsová J
Hepatogastroenterology; 1997; 44(15):886-90. PubMed ID: 9222709
[TBL] [Abstract][Full Text] [Related]
28. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer.
Beker JA; Bianchi Porro G; Bigard MA; Delle Fave G; Devis G; Gouerou H; Maier C
Eur J Gastroenterol Hepatol; 1995 May; 7(5):407-10. PubMed ID: 7614102
[TBL] [Abstract][Full Text] [Related]
29. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Brunner G; Harke U
Aliment Pharmacol Ther; 1994; 8 Suppl 1():59-64. PubMed ID: 8180296
[TBL] [Abstract][Full Text] [Related]
30. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
Richter JE; Bochenek W
Am J Gastroenterol; 2000 Nov; 95(11):3071-80. PubMed ID: 11095320
[TBL] [Abstract][Full Text] [Related]
31. Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter randomized, double-blind study.
Jensen DM; Pace SC; Soffer E; Comer GM;
Am J Gastroenterol; 2006 Sep; 101(9):1991-9; quiz 2170. PubMed ID: 16968504
[TBL] [Abstract][Full Text] [Related]
32. Pantoprazole versus ranitidine in the treatment of duodenal ulcer: a multicenter study in Brazil.
Meneghelli UG; Zaterka S; de Paula Castro L; Malafaia O; Lyra LG
Am J Gastroenterol; 2000 Jan; 95(1):62-6. PubMed ID: 10638560
[TBL] [Abstract][Full Text] [Related]
33. The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing.
Sivri B; Simsek I; Hulagu S; Kadayifci A; Tozun N; Akarsu M; Uraz S; Savas MC; Koruk M; Bozbas A
Curr Med Res Opin; 2004 Aug; 20(8):1301-7. PubMed ID: 15324533
[TBL] [Abstract][Full Text] [Related]
34. One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis.
Mössner J; Koop H; Porst H; Wübbolding H; Schneider A; Maier C
Aliment Pharmacol Ther; 1997 Dec; 11(6):1087-92. PubMed ID: 9663834
[TBL] [Abstract][Full Text] [Related]
35. Pantoprazole-induced recurrent anaphylactic shock.
Fardet L; Izzedine H; Ciroldi M; Tiev KP; Cabane J
Am J Gastroenterol; 2002 Nov; 97(11):2933. PubMed ID: 12425583
[No Abstract] [Full Text] [Related]
36. Pantoprazole versus omeprazole in the treatment of reflux esophagitis.
Vcev A; Stimac D; Vceva A; Takac B; Ivandić A; Pezerović D; Horvat D; Nedić P; Kotromanović Z; Maksimović Z; Vranjes Z; Males J; Jurisić-Orzen D; Vladika I; Stimac T; Mandić B
Acta Med Croatica; 1999; 53(2):79-82. PubMed ID: 10705625
[TBL] [Abstract][Full Text] [Related]
37. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
38. Safety of proton pump inhibitors--an overview.
Arnold R
Aliment Pharmacol Ther; 1994; 8 Suppl 1():65-70. PubMed ID: 8180297
[TBL] [Abstract][Full Text] [Related]
39. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
[TBL] [Abstract][Full Text] [Related]
40. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
Regula J; Butruk E; Dekkers CP; de Boer SY; Raps D; Simon L; Terjung A; Thomas KB; Lühmann R; Fischer R
Am J Gastroenterol; 2006 Aug; 101(8):1747-55. PubMed ID: 16817839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
